ReviR Therapeutics, a Brisbane, CA-based biotechnology company focused on AI-enabled drug discovery, secured $30M in Series A funding.

The round was led by Lapam Capital, with significant contributions from CDH Investments, 5Y Capital, Yael Capital, XtalPi, and the Charcot-Marie Tooth Research Foundation (CMTRF).

Funds will enhance the AI-driven VoyageR platform aimed at developing small molecule RNA modulators for neurogenetic diseases like Huntington's, CMT, and ALS.

Founded in 2021 by Dr. Peng Yue, ReviR is pioneering RNA-targeting therapies for CNS diseases and rare genetic disorders. The company’s SpliceR modulation technology aims to create disease-modifying treatments with high specificity and safety.